Thus, the inhibition of osteoclast formation, bone resorption and migration by inhibiting RANKL signaling and downstream pathways is an important target in the treatment of osteoporosis (Zou et al., 2001; Xuan et al., 2017). The gene discussed is TNFSF11; the disease is osteoporosis.